Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...
Merck's SWOT analysis: pharma giant's stock faces China setback, PAH potential
Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?
AKRO stock hits 52-week high, soaring to $56.86
Akero Therapeutics Inc . stock (NASDAQ:AKRO) reached a new 52-week high this trading session, with shares climbing to an ...
FiercePharma6d
After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...